Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Zemdri (plazomicin) is indicated for the treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI), including pyelonephritis.
• This summary is based on the review of one randomized controlled trial(s). ^[1]
• Day 5 Composite Cure Rates for complicated UTIs and acute pyelonephritis: Plazomicin achieved a cure rate of 88.0% (168/191) compared to 91.4% (180/197) with meropenem, with a difference of -3.4 percentage points (95% CI, -10.0 to 3.1).
• Test-of-Cure Composite Cure Rates (15 to 19 days after initiation): Plazomicin had a cure rate of 81.7% (156/191) versus 70.1% (138/197) with meropenem, showing a difference of 11.6 percentage points (95% CI, 2.7 to 20.3).
• Late Follow-Up Outcomes (24 to 32 days after initiation): Plazomicin resulted in lower microbiologic recurrence (3.7%) and clinical relapse (1.6%) compared to meropenem, which had rates of 8.1% and 7.1%, respectively.
• An increase in serum creatinine levels (≥0.5 mg/dL above baseline) was observed in 7.0% of patients treated with plazomicin, compared to 4.0% in those treated with meropenem.
• There is no population types or subgroups information available in the reviewed studies.